|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Mendlsohn J and Baserga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
4
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar
|
|
5
|
Nakagawa K, Tamura T, Negoro S, et al:
Phase I pharmacokinetic trial of the selective oral epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib
(‘Iressa’, ZD1839) in Japanese patients with solid malignant
tumours. Ann Oncol. 14:922–930. 2003.
|
|
6
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
|
|
7
|
Peled N, Wynes MW, Ikeda N, et al:
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for
resistance to the tyrosine kinase inhibitor gefitinib in non-small
cell lung cancer. Cell Oncol (Dordr). 36:277–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roybal JD, Zang Y, Ahn YH, et al: miR-200
inhibits lung adenocarcinoma cell invasion and metastasis by
targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A, Trang P, Wiggins JF,
et al: The let-7 microRNA reduces tumor growth in mouse models of
lung cancer. Cell Cycle. 7:759–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambros V: microRNAs: tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung AK and Sharp PA: microRNAs: a
safeguard against turmoil? Cell. 130:581–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coldren CD, Helfrich BA, Witta SE, et al:
Baseline gene expression predicts sensitivity to gefitinib in
non-small cell lung cancer cell lines. Mol Cancer Res. 4:521–528.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uphoff CC and Drexler HG: Detecting
mycoplasma contamination in cell cultures by polymerase chain
reaction. Methods Mol Biol. 731:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gainor JF and Shaw AT: Emerging paradigms
in the development of resistance to tyrosine kinase inhibitors in
lung cancer. J Clin Oncol. 31:3987–3996. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L, Liu Y, Bai Y, Sun Y, Xiao F and Guo
Y: Gene expression profiling of drug-resistant small cell lung
cancer cells by combining microRNA and cDNA expression analysis.
Eur J Cancer. 46:1692–1702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nguemo F, Šarić T, Pfannkuche K, Watzele
M, Reppel M and Hescheler J: In vitro model for assessing
arrhythmogenic properties of drugs based on high-resolution
impedance measurements. Cell Physiol Biochem. 29:819–832. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maftouh M, Avan A, Galvani E, Peters GJ
and Giovannetti E: Molecular mechanisms underlying the role of
microRNAs in resistance to epidermal growth factor
receptor-targeted agents and novel therapeutic strategies for
treatment of non-small-cell lung cancer. Crit Rev Oncog.
18:317–326. 2013. View Article : Google Scholar
|
|
20
|
Kitamura K, Seike M, Okano T, et al:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:44–453. 2014.PubMed/NCBI
|
|
21
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
An IS, An S, Kwon KJ, Kim YJ and Bae S:
Ginsenoside Rh2 mediates changes in the microRNA expression profile
of human non-small cell lung cancer A549 cells. Oncol Rep.
29:523–528. 2013.PubMed/NCBI
|
|
23
|
Garofalo M, Romano G, Di Leva G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011.
|
|
24
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giles KM, Barker A, Zhang PM, Epis MR and
Leedman PJ: MicroRNA regulation of growth factor receptor signaling
in human cancer cells. Methods Mol Biol. 676:147–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Webster RJ, Giles KM, Price KJ, Zhang PM,
Mattick JS and Leedman PJ: Regulation of epidermal growth factor
receptor signaling in human cancer cells by microRNA-7. J Biol
Chem. 284:5731–5741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X and Carthew RW: A microRNA mediates
EGF receptor signaling and promotes photorecepotor differentiation
in the Drosophila eye. Cell. 123:1267–1277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang L, Liu X, Chen Z, et al: MicroRNA-7
targets IGF1R (insulin-like growth factor 1 receptor) in tongue
squamous cell carcinoma cells. Biochem J. 432:199–205. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stark A, Brennecke J, Russell RB and Cohen
SM: Identification of Drosophila microRNA targets. PLoS Biol.
1:E602003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reddy SD, Ohshiro K, Rayala SK and Kumar
R: MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase
1 and regulates its functions. Cancer Res. 68:8195–8200. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Masuda M, Miki Y, Hata S, et al: An
induction of microRNA, miR-7 through estrogen treatment in breast
carcinoma. J Transl Med. 10:S22012. View Article : Google Scholar : PubMed/NCBI
|
